Recombinant activated factor VII (Novo7®) in patients with ventricular assist devices: Case report and review of the current literature
2007

Using Recombinant Activated Factor VII in Patients with Ventricular Assist Devices

Sample size: 5 publication Evidence: low

Author Information

Author(s): Heise Daniel, Bräuer Anselm, Quintel Michael

Primary Institution: University Hospital Goettingen, Department of Anesthesiology, Emergency and Intensive Care Medicine, Goettingen, Germany

Hypothesis

Can recombinant activated factor VII (rFVIIa) effectively treat uncontrolled bleeding in patients with ventricular assist devices (VAD)?

Conclusion

The use of rFVIIa appears to be a promising therapeutic option for managing massive non-surgical bleeding in patients with VAD.

Supporting Evidence

  • In all cases reviewed, cessation of bleeding without thrombembolic complications was achieved after administering rFVIIa.
  • The case report highlighted a patient who stopped bleeding within minutes after receiving rFVIIa.
  • The literature review included four other cases where rFVIIa was used successfully in patients with VAD.

Takeaway

Doctors can use a special medicine called rFVIIa to help stop bleeding in patients who have heart devices, even when other treatments don't work.

Methodology

The authors reviewed case reports and presented a case from their hospital regarding the use of rFVIIa in patients with VAD.

Potential Biases

Potential bias due to the small sample size and reliance on case reports.

Limitations

The study is based on a limited number of case reports, and the outcomes of some cases remain unclear.

Participant Demographics

The case reports included patients with various ages and conditions requiring VAD.

Digital Object Identifier (DOI)

10.1186/1749-8090-2-47

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication